Jazz Pharmaceuticals plc
JAZZ
$229.63
$0.440.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.20% | 4.88% | 4.13% | 4.52% | 5.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.20% | 4.88% | 4.13% | 4.52% | 5.76% |
| Cost of Revenue | 17.45% | 14.20% | 13.18% | 11.32% | 13.49% |
| Gross Profit | 8.33% | 3.92% | 3.23% | 3.85% | 5.01% |
| SG&A Expenses | -4.39% | 17.96% | 20.00% | 17.61% | 15.95% |
| Depreciation & Amortization | 7.43% | 4.35% | 3.84% | 2.51% | 1.91% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.22% | 6.90% | 9.05% | 6.38% | 7.13% |
| Operating Income | 57.35% | -3.42% | -15.49% | -3.84% | -0.75% |
| Income Before Tax | -160.62% | -234.10% | -277.47% | -273.24% | 51.90% |
| Income Tax Expenses | -105.57% | -197.97% | -403.42% | -8.23% | -30.11% |
| Earnings from Continuing Operations | -93.88% | -163.58% | -179.55% | -202.50% | 45.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.88% | -163.58% | -179.55% | -202.50% | 45.78% |
| EBIT | 57.35% | -3.42% | -15.49% | -3.84% | -0.75% |
| EBITDA | 32.62% | 0.61% | -6.15% | -0.22% | 0.89% |
| EPS Basic | -94.01% | -163.51% | -179.94% | -205.11% | 49.60% |
| Normalized Basic EPS | 129.94% | 5.09% | -12.89% | 6.64% | 13.50% |
| EPS Diluted | -100.32% | -168.00% | -185.54% | -215.65% | 54.71% |
| Normalized Diluted EPS | 133.49% | 6.80% | -7.84% | 15.72% | 20.02% |
| Average Basic Shares Outstanding | -0.40% | -1.38% | -2.40% | -2.77% | -2.53% |
| Average Diluted Shares Outstanding | -1.16% | -3.74% | -7.44% | -9.61% | -7.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |